Most pharma companies want to ensure their drugs are effective for the greatest portion of the patient populations they are designed to treat. An important part of designing effective clinical

Hunter syndrome patients can manage the disorder with a drug that addresses disease symptoms throughout the body except the brain — a key limitation for treating this rare neurological disorder.

As a member of the Coalition Against Surprise Medical Billing, Katy Spangler helped push for the No Surprises Act in 2020. However, on Wednesday, she took the stage at the

Cell and gene therapies (CGTs) are built on living systems. From early research through commercial distribution, the integrity of those systems depends on the ability to preserve cells without compromising

In the past few years, payers and providers have been engaged in an arms race when it comes to deploying AI, with insurers using the technology to deny claims faster

H.R. 1, known as the One Big Beautiful Bill Act, will enact significant changes to Medicaid in January 2027, including work requirements for certain enrollees to maintain eligibility. It’s estimated

Merck is picking up a big new piece for its cancer drug pipeline with a $6.7 billion deal to acquire Terns Pharmaceuticals, a company whose lead program could rival a

Affordability is top of mind for executives at AHIP as Americans battle skyrocketing healthcare costs. “We are laser-focused on affordability at AHIP,” said Mike Tuffin, president and CEO of AHIP.

At Wayne General Hospital in rural Mississippi, clinicians say AI-powered stethoscope usage is helping them detect heart problems earlier in patients who often have limited access to specialists. The hospital’s

A patient calls their gastroenterologist’s office with worsening symptoms. The first available appointment is in three months. By the time they’re seen, what started as manageable has become serious, requiring